Project Grant K08AI202228
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- Federal Grant Award Summary Seattle Children's Research Institute received a $516,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 23, 2025, with a completion date of May 31, 2027. The award funds research evaluating the impact of pre-existing humoral immunity on hepatocyte death in the context of malaria infection and vaccine efficacy. The research addresses a...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $220,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a dual germline-targeting immunization strategy eliciting broadly neutralizing antibodies against HIV-1. The research uses preclinical transgenic mouse models and data from an ongoing Phase 1 clinical trial (HVTN301) to optimize a prime-boost vaccination approach with the germline-targeting...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $220,000 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop statistical methods for assessing immune correlates of risk and protection using flexible two-phase sampling designs. The project develops novel two-phase sampling designs—such as case-cohort or case-control studies—that enrich longitudinal immune response marker measurements in immune...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $879,998 on July 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of mucosal regulatory T cells in modulating tissue-resident memory T cell responses to infection. The research defines the features, fate, mechanisms, and functional consequences of regulatory T cells (Treg) and tissue Treg in anti-viral tissue memory immune responses in mice and...
- The National Institute of Allergy and Infectious Diseases awarded $922,799 to Seattle Children's Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bioengineered human brain microvessel platforms for modeling cerebral malaria disease mechanisms and developing adjunctive therapies. The research addresses the pathogenesis of cerebral malaria caused by Plasmodium falciparum, which leads to sequestration of infected red...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $278,333 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess the longitudinal impact of VRC01 prophylaxis on viral populations and autologous antibody responses in breakthrough infections. The research leverages longitudinal data from the Antibody Mediated Protection (AMP) Trial HVTN 704 and the follow-up Analytic Treatment Interruption (ATI) Trial...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $323,892 on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research training program in mathematical modeling of SARS-CoV-2 variant emergence from immunocompromised hosts. The award funds development of a suite of mathematical models to understand mechanisms facilitating generation of SARS-CoV-2 variants of concern during prolonged...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $552,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct functional characterization of dendritic cell heterogeneity for T cell-inducing immunotherapies. The research addresses vaccine development for intracellular pathogens including HIV/AIDS and malaria by investigating the distinct roles of type 1 and type 2 conventional dendritic cells in...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $870,131 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define DNA double-strand break repair mechanisms in Plasmodium falciparum and their role in antigenic variation and genome integrity maintenance. The research examines how the malaria parasite repairs DNA damage—specifically double-strand breaks—which the investigator proposes enables...